Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
3
×
boston blog main
boston top stories
life sciences
national blog main
national top stories
new york blog main
new york top stories
san diego blog main
san diego top stories
san francisco blog main
san francisco top stories
boulder/denver blog main
boulder/denver top stories
bristol-myers squibb
celgene
deals
detroit blog main
detroit top stories
genentech
indiana blog main
indiana top stories
intercept pharmaceuticals
national
raleigh-durham blog main
raleigh-durham top stories
seattle blog main
seattle top stories
startups
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
2019
4d molecular therapeutics
abbvie
acetylon pharmaceuticals
acne
activism
acute hepatic porphyria
What
liver
3
×
bio
disease
drug
race
roundup
advanced
aiming
alnylam’s
ambys
approval
approved
bff
big
biotech
companies
conference
control
deadly
deal
deals
debuted
devoted
digital
diseases
easl
epidemic
fatty
fda
form
formed
frenzied
future
gene
growing
kicked
known
launch
led
major
Language
Current search:
liver
×
biotech
×
@xconomy.com
5 years ago
Bio Roundup: EASL Does It, Alnylam’s BFF, Gene Therapy Deals & More
@xconomy.com
5 years ago
Bio Roundup: NASH News, Merck Strikes, Digital Tokens & More
@xconomy.com
5 years ago
With Big Takeda Deal at Launch, Can Ambys Keep Control of Its Future?
